Advantages of Tyrosine Kinase Anti-Angiogenic Cediranib over Bevacizumab: Cell Cycle Abrogation and Synergy with Chemotherapy

• Asıl Yazarlar: Jianling Bi (Yazar), Garima Dixit (Yazar), Yuping Zhang (Yazar), Eric J. Devor (Yazar), Haley A. Losh (Yazar), Andreea M. Newtson (Yazar), Kristen L. Coleman (Yazar), Donna A. Santillan (Yazar), Thorsten Maretzky (Yazar), Kristina W. Thiel (Yazar), Kimberly K. Leslie (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: MDPI AG, 2021-07-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Angiogenesis plays a crucial role in tumor development and metastasis. Both bevacizumab and cediranib have demonstrated activity as single anti-angiogenic agents in endometrial cancer, though subsequent studies of bevacizumab combined with chemotherapy failed to improve outcomes compared to chemothe...